Gilead Sciences

Gilead details its case for a new HIV flagship triple, with megablockbuster potential
Gilead details its case for a new HIV flagship triple, with megablockbuster potential
Endpoints
Gilead Sciences
HIV
bictegravir
FTC/TAF
Flag link:
Gilead Has Another Ace Up Its Sleeve
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha
Gilead Sciences
hepatitis C
Vosevi
Flag link:
FDA's Flashing Green Light Boosts Novel Drug Approvals
FDA's Flashing Green Light Boosts Novel Drug Approvals
Seeking Alpha
FDA
drug approvals
Gilead Sciences
Puma Biotechnology
Vosevi
Nerlynx
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
5 Ways Gilead Sciences Could Spend Its Cash Hoard
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Motley Fool
Gilead Sciences
dividends
share repurchase
M&A
debt
Flag link:
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
Endpoints
Gilead Sciences
FDA
hepatitis C
Vosevi
Flag link:
5 Big Pharma Stocks With the Best Drug Pipelines
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
Flag link:
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Motley Fool
Gilead Sciences
M&A
Flag link:
Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?
Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?
Fierce Pharma
Tesaro
Gilead Sciences
Incyte
M&A
Flag link:
Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive
Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive
Endpoints
M&A
Gilead Sciences
Incyte
Vertex Pharmaceuticals
John Milligan
Flag link:
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
Yahoo/Zacks.com
earnings
Merck
Eli Lilly
Celgene
Gilead Sciences
Shire
Flag link:
Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Fierce Pharma
Gilead Sciences
FDA
HIV
whistleblower lawsuits
Flag link:
What Gilead Could Learn From Celgene
What Gilead Could Learn From Celgene
Seeking Alpha
Gilead Sciences
Celgene
Flag link:
How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
Motley Fool
Gilead Sciences
M&A
CV Therapeutics
CGI Pharma
Arresto Biosciences
Calistoga Pharmaceuticals
Pharmasset
YM BioSciences
EpiTherapeutics
Flag link:
3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals
3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals
Motley Fool
Gilead Sciences
Vertex Pharmaceuticals
Flag link:
Gilead's best M&A option? It's not oncology—it's Vertex, analyst insists
Gilead's best M&A option? It's not oncology—it's Vertex, analyst insists
Fierce Pharma
Gilead Sciences
M&A
Vertex Pharmaceuticals
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Gilead buy Vertex? A golden oldie in the M&A buzz circuit gets fresh air time
Gilead buy Vertex? A golden oldie in the M&A buzz circuit gets fresh air time
Endpoints
Gilead Sciences
Vertex Pharmaceuticals
M&A
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link: